Merck's discount wins NICE nod for Keytruda; FDA flags user-error worries with Purdue's new painkiller;

> Merck & Co.'s ($MRK) new cancer immunotherapy Keytruda won backing from the U.K.'s cost-effectiveness watchdogs after offering an unspecified discount. Report

> FDA staff reviewers flagged likely errors in administering Purdue Pharma's new fast-acting oxycodone painkiller, saying taking the drug with food can interfere with its effectiveness. Report

> Canadian regulators cleared Recordati's rare disease drug Carbaglu for marketing, as a treatment for hyperammonemia. Report

> Two leading U.S. physicians' organizations say proposed megamergers in the health insurance business will be anti-competitive. Report

And Finally... U.K. life sciences groups, including pharma companies, urged the government not to cut research funding, citing the economic benefits of R&D work. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.